DVA vs SNY
DaVita vs Sanofi — AI-powered side-by-side comparison
| Metric | DVA | SNY |
|---|
| AI Score |
53
|
66
|
| Price |
$177.63
|
$46.00
|
| P/E Ratio |
15.18×
|
24.00×
|
| ROE |
-114.7%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
31.0%
|
72.8%
|
| Debt / Equity |
-14.09×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.3%
|
| RSI (14) |
28.1
|
67.8
|
| Beta |
0.87
|
0.278
|
| Expected Upside |
+1.8%
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for DVA versus SNY.
SNY leads by 13 points.
SNY scores 66/100 (Buy) versus DVA at 53/100 (Watch).
DVA Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 3 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — high leverage (debt-to-equity 77.99) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 13.6 is inexpensive for the broad market — Value
- ROE of 181.2% shows genuine earnings power backing the valuation — Value
- 3 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 101.2x prices in significant intangible value — Value
- Debt-to-equity of 77.99 adds balance-sheet risk to the value case — Value
- RSI at 28 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 4.1% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth